Tony R Reid
Overview
Explore the profile of Tony R Reid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reid T, Oronsky B, Williams J, Caroen S, Conley A
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39461878
At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a...
2.
Conley A, Larson C, Oronsky B, Stirn M, Caroen S, Reid T
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38886116
The purpose of this commentary is to highlight the high occurrence of clinical pseudoprogression and delayed responses that have been observed to date with the locally injected oncolytic adenovirus, AdAPT-001,...
3.
Conley A, Roland C, Bessudo A, Gastman B, Villaflor V, Larson C, et al.
Cancer Gene Ther
. 2023 Dec;
31(4):517-526.
PMID: 38146006
AdAPT-001 is an oncolytic adenovirus (OAV) with a transforming growth factor beta (TGF-ß) trap, which neutralizes the immunosuppressive and profibrotic cytokine, TGF-ß. The aim or purpose of this phase 1...
4.
Larson C, Oronsky B, Reid T
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38135348
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food...
5.
Oronsky B, Cabrales P, Alizadeh B, Caroen S, Stirn M, Williams J, et al.
Future Oncol
. 2023 Jul;
19(30):2013-2015.
PMID: 37503560
No abstract available.
6.
Oronsky B, Burbano E, Stirn M, Brechlin J, Abrouk N, Caroen S, et al.
Clin Transl Sci
. 2023 Jun;
16(9):1497-1509.
PMID: 37382299
In drug development a frequently used phrase is "data-driven". Just as high-test gas fuels a car, so drug development "runs on" high-quality data; hence, good data management practices, which involve...
7.
Hammond T, Lee R, Oronsky B, Reid T, Caroen S, Juarez T, et al.
Int Med Case Rep J
. 2022 Dec;
15:735-738.
PMID: 36545548
Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular...
8.
Reid T, Abrouk N, Caroen S, Oronsky B, Stirn M, Larson C, et al.
Clin Colorectal Cancer
. 2022 Dec;
22(1):92-99.
PMID: 36529613
Introduction: RRx-001 is a novel cysteine-targeted alkylating agent that releases nitric oxide (NO). The primary biological activities of this hybrid molecule include macrophage repolarizing and vascular normalization. The purpose of...
9.
Oronsky B, Larson C, Caroen S, Reid T
Int J Infect Dis
. 2022 Nov;
125:227.
PMID: 36347457
No abstract available.
10.
Oronsky B, Caroen S, Abrouk N, Reid T
Life Sci Space Res (Amst)
. 2022 Nov;
35:69-75.
PMID: 36336372
From antibiotics to aspirin to antimalarials and to anticancer agents, about half of the world's best-selling drugs are derived from nature. However, accelerating climatic disruption, habitat destruction, pollution, and biodiversity...